Friday, 17 September 2021

 

 

NEWS FLASH 68th Meeting of Shri Mata Vaishno Devi Shrine Board Lt Governor, Manoj Sinha releases former MLC Ramesh Arora’s poetry collection ‘Anubhutiyan’ Deputy Commissioner Jammu chairs maiden DTC meeting MP Jugal Kishore Sharma flags off Freedom Run at Samba Union MSME Minister, Narayan Tatu Rane lays foundation stone for development park at Bari Brahmana, Samba Union Minister for Tribal Affairs visits Bandipora, inaugurates several projects Union MoS, Som Parkash interacts with representatives of Trade bodies Union AYUSH Minister Sarbananda Sonowa visits Baramulla Union MoS, Som Parkash reviews functioning of I&C Deptt. Union Minister of State for Communication visits Indian International Trade Saffron Spice Park at Pampore Deputations, individuals call on Advisor Baseer Khan at Civil Secretariat Advisor Baseer Ahmad Khan reviews progress on replacement of Barbed wire, poles Union Minister Arjun Ram Meghwal flags off cycle rally by riding himself at Udhampur Lt Governor attends Passing out Parade of 669 cadets of J&K Fire and Emergency Services Union MOS for Petroleum, Natural Gas and Labour & Employment, Rameswar Teli visits Doda DC Srinagar, Mohammad Aijaz Asad visits Shrine of Hazrat Sheikh Hamza Makhdoom(RA) District-Level Environment Committee reviews implementation of Conservation Plan DDC Chairperson Ramban, Dr. Shamshad Shan reviews progress on District Capex Plan, 2021-22, Area Development Funds DC Srinagar, Mohammad Aijaz Asad holds interaction with Tourism Associations Divisional Commissioner, Pandurang Kondbara Pole chairs SSCL meeting for Development of Srinagar Riverfront Phase-I Workshop on formulation of rules, regulations regarding implementation of RTE Act 2009 concludes

 

Hetero announces interim clinical results of Molnupriavir

Delta Plus Covid variant, Delta Covid-19 variant, Coronavirus, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Covifor, Oxygen supply, Oximeter, Hetero, Molnupriavir

Web Admin

Web Admin

5 Dariya News

Hyderabad , 09 Jul 2021

Hetero, a globally renowned vertically integrated pharmaceutical organization, on Friday announced the interim clinical results from Phase III clinical trials of Molnupiravir in mild Covid-19 patients conducted across multiple Covid-dedicated hospital sites across India.The trials demonstrated statistically significant fewer hospital admissions, faster time to clinical improvement and early negative SARS CoV-2 RT PCR with Molnupiravir treatment in mild COVID-19 patients Compared to Standard of Care alone.The company said it has approached the Drug Controller General of India (DCGI) to seek emergency use authorization for Molnupiravir in India.In April this year, Hetero had entered into a non-exclusive licensing agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., the US, to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).Molnupiravir is an investigational, orally administered form of a potent ribonucleoside analog, being developed globally by MSD, that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of Covid-19 with demonstrated activity against SARS-CoV-2 in human airway epithelial cell cultures and potential to completely eliminate SARS CoV-2 from the body within 5 days.

Hetero had commenced a phase-III, comparative, randomized, multicenter clinical trial on 1,218 mild Covid-19 patients. These clinical trials were aimed at evaluating the efficacy and safety of Molnupiravir plus standard of care (test arm) versus standard of care alone (control arm), in mild Covid-19 patients with a positive SARS CoV-2 RT PCR test for Covid-19 and randomized within 5 days of onset of symptoms.Patients in the clinical trial were randomized to receive either Hetero's Molnupiravir capsules 800 mg (4 x 200 mg) every 12 hours (twice daily) for 5 days along with standard of care as per the Indian Council of Medical Research (ICMR) guidelines or, in the control arm, to receive standard of care alone.The company said the interim results from 741 mild Covid-19 patients revealed encouraging outcomes.Earlier clinical improvement (2-point decrease in WHO Clinical Progression Scale) was observed in Molnupiravir group compared to standard of careMedian time to clinical improvement was as early as 8 days in Molnupiravir group compared to 12 days in standard of care alone group.Earlier SARS CoV-2 RT-PCR negativity observed in Molnupiravir group compared standard of care. There were fewer hospital admissions in Molnupiravir groupThere was no mortality in either group. All adverse events were non-serious, mild in severity, and none led to drug discontinuation. Most common adverse events reported were nausea, diarrhoea and headache which were resolved completely.In addition to these clinical trial studies, Hetero is also undertaking a separate Molnupiravir study on moderate Covid-19 patients approved by CDSCO. The interim and final clinical results on the same will be shared in due course.

 

Tags: Delta Plus Covid variant , Delta Covid-19 variant , Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Covifor , Oxygen supply , Oximeter , Hetero , Molnupriavir

 

 

related news

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
Copyright 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD